Insights On Upstream Manufacturing
-
A Robust System For High-Titer, Platform-Agnostic AAV Production In HEK293 Cells
10/23/2026
AAV titer and full capsid enrichment depend on tuning every process component, starting with the medium. Results across serotypes, reagents, and enhancers show how far a media-led approach can go.
-
Maintaining Process Consistency And Performance During Scale-Up
10/22/2026
See how an intensified N-1 perfusion process maintained stable cultures, reproducible cell expansion, and aligned mAb production across 5 L, 50 L, and 500 L scales while supporting viable cell densities.
-
Maximize Exosome Yields Using a Chemically Defined Bioreactor Media System
10/22/2026
See how scalable processes can improve exosome yield and recovery while maintaining critical quality attributes and supporting clinical manufacturing.
-
High-Throughput Binding Affinity Assessment Using Octet® HTX
10/22/2026
Binding affinity screening of clones directly from crude supernatant, without purification, changes what can be assessed early, and a tiered workflow pairs broad throughput with deeper analytical characterization.
-
Beyond Speed And Titer: Building Cell Lines For Long-term Development Success
10/20/2026
Cell line development is often judged by speed and titer, but true readiness depends on manufacturability, analytics, stability, and regulatory support.
-
Strategic Frameworks For Cell Line Development: Long-Term Program Viability
10/20/2026
Speed to cell bank alone doesn't predict success. Early decisions around manufacturability, analytics, stability, and regulatory strategy determine whether a program can scale.
-
How Can We Build Trust In Model-Driven Manufacturing?
10/15/2026
Data is abundant, but turning it into trusted prediction is harder. Model-driven control depends on process understanding, organizational capability, and trust as much as technology.
-
Navigating One Of Biomanufacturing's Most Contentious Decisions
10/15/2026
Single-use and stainless steel bioreactors share core engineering, so real differences lie in the operations. See how the development stage and commercial trajectory outweigh allegiance to either.
-
Amino Acids For cGMP Biopharmaceutical Manufacturing
10/15/2026
cGMP-grade amino acids require more than chemical specifications. Documentation, supplier controls, traceability, and intended use shape suitability for regulated processes.
-
Why Reagent Quality Defines Research Success
10/15/2026
Water grade, buffer preparation, and packaging each shape whether sensitive assays hold up. Reagent selection hinges on matching purity to application sensitivity, regulatory standards, and tolerance for contamination risk.